Get started
Author

Sa Xiao

BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study.
2023 · Li Zhang, Yuxiang Ma, et al. · Journal of Clinical Oncology · 29
Establishment and evaluation of four different types of patient-derived xenograft models
2017 · Xiaoqian Ji, Siyu Chen, et al. · Cancer Cell International · 28
PDF
Ribosome Hibernation as a Stress Response of Bacteria
2020 · Tianwen Wang, Chen Liang, et al. · Protein and Peptide Letters · 22
Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al. · Clinical Cancer Research · 19
PDF
SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
2023 · Yuanyuan Zhao, Li Zhang, et al. · Journal of Clinical Oncology · 19
Engineering the Translational Machinery for Biotechnology Applications
2020 · Tianwen Wang, Chen Liang, et al. · Molecular Biotechnology · 19
Insulin-like growth factor binding protein-1 and insulin in polycystic ovary syndrome: a systematic review and meta-analysis
2023 · Yuxin Jin, Fei Sun, et al. · Frontiers in Endocrinology · 18
Small design from big alignment: engineering proteins with multiple sequence alignment as the starting point
2020 · Tianwen Wang, Chen Liang, et al. · Biotechnology Letters · 18
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations.
2025 · Yunpeng Yang, Li Zhang, et al. · Journal of Clinical Oncology · 13
PDF
A Novel miRNA—hlo-miR-2—Serves as a Regulatory Factor That Controls Molting Events by Targeting CPR1 in Haemaphysalis longicornis Nymphs
2020 · Wen-Ge Liu, Jin Luo, et al. · Frontiers in Microbiology · 13
PDF
An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma
2018 · Ling Li, Sa Xiao, et al. · Oncotarget · 13
PDF
Results from two phase II studies of SI-B001, an EGFR×HER3 bispecific antibody, with/without chemotherapy in patients (pts) with recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).
2023 · Liqiong Xue, Kunyu Yang, et al. · Journal of Clinical Oncology · 11
Transcriptional factor engineering in microbes for industrial biotechnology
2020 · Tianwen Wang, Chen Liang, et al. · Journal of Chemical Technology & Biotechnology · 10
Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC).
2025 · Yan Huang, Li Zhang, et al. · Journal of Clinical Oncology · 9
SI-B003 (PD-1/CTLA-4) in patients with advanced solid tumors: A phase I study.
2023 · Yakun Wang, Yongsheng Li, et al. · Journal of Clinical Oncology · 7
PDF
Antisense and RNAi expression for a chloroplastic superoxide dismutase gene in transgenic plants
2005 · Shuyan Chen, Sa Xiao, et al. · Lanzhou University Institutional Repository · 6
Abstract PO2-04-03: BL-M07D1, an antibody-drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study
2024 · Erwei Song, Herui Yao, et al. · Cancer Research · 5
Abstract PS08-07: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Results from a phase 1 study
2024 · Jiong Wu, Jian Zhang, et al. · Cancer Research · 4
Abstract P5-07-27: BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with Locally Advanced or Metastatic Breast Cancer and other Solid Tumor: Updated results from a phase 1 study
2025 · Jiong Wu, Jian Zhang, et al. · Clinical Cancer Research · 2
Efficacy and Safety of Novel Targeted Drug' Apatinib in Relapse or Refractory Non-Hodgkin Lymphoma: An Open Label, Single-Armed, Exploratory Study
2017 · Ling Li, Sa Xiao, et al. · Blood · 2
Figure 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Data from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Figure 3 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Figure 2 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Supplementary Figure S1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
2025 · Jinhui Xue, Yuxiang Ma, et al.
Works count: 39
Citation count: 267
H-index: 11
I10-index: 13
Year
Topic
Type